Novartis India has launched Pluvicto (lutetium 177Lu vipivotide tetraxetan), the country’s first regulatory-approved radioligand therapy for advanced, PSMA-positive metastatic castration-resistant prostate cancer. Delivered via select nuclear medicine networks, this targeted precision treatment delivers destructive radiation directly to cancer cells while preserving surrounding healthy tissues.
Global healthcare pioneer Novartis India has officially announced the commercial launch of its breakthrough radioligand therapy, Pluvicto, within the Indian market. The treatment, scientifically known as lutetium (177Lu) vipivotide tetraxetan, represents the nation’s first regulatory authority-approved radioligand therapy for patients battling progressive, Prostate-Specific Membrane Antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This strategic launch by Novartis marks a definitive shift in the domestic oncology paradigm, shifting care toward highly precise molecular targeting at a time when advanced prostate cancer rates are escalating across the country.
Direct Cellular Targeting Modality In Oncology
The introduction of the Novartis radioligand therapy Pluvicto in India introduces a sophisticated mechanism that functions as a precision-guided treatment. The therapy combines a specialized targeting compound, or ligand, with a therapeutic radioisotope called lutetium-177.
When administered via intravenous infusion, the molecule circulates through the bloodstream and binds specifically to the PSMA transmembrane proteins widely expressed on the surface of advanced prostate cancer cells. Once bound, the radioisotope emits targeted beta radiation over a short radius. This localized energy directly damages the DNA of the malignant cells, halting replication and triggering cellular death while substantially restricting radiation exposure to surrounding healthy bodily tissues.
Expanding Access Through Nuclear Medicine Infrastructure
Managing late-stage oncology cases requires specialized clinical logistics. According to executive briefings from Novartis India, the deployment of Pluvicto will rely heavily on partnerships with certified hospital networks and established nuclear medicine centers. This rollout model aims to ensure that healthcare institutions possess the specialized radiopharmaceutical handling capabilities and isolation facilities required for therapeutic infusions.
Historically, a profound challenge in Indian healthcare has been late-stage diagnosis. Due to a general lack of routine screening, a significant proportion of local prostate cancer cases are identified only after the disease has metastasized. The arrival of Pluvicto provides Indian oncologists with an internationally validated, non-chemotherapeutic option to manage advanced disease pathways, potentially maintaining the quality of life for individuals whose tumors have stopped responding to standard hormone interventions.
Industrial and Logistical Impact
For the domestic pharmaceutical and healthcare investment sector, the launch of an advanced radioligand therapy underscores the rapid maturation of India’s healthcare delivery infrastructure. Radioligand therapies feature strict radioactive decay timelines, meaning the global supply chain, precision shipping, and localized hospital delivery must be perfectly synchronized.
The successful commercial integration of Pluvicto is expected to accelerate domestic investments in specialized oncology equipment, radiopharmaceutical manufacturing facilities, and comprehensive training modules for nuclear medicine technicians across major Indian medical centers.
Official Sources Section
Regulatory approvals, clinical indications, and distribution frameworks for the therapeutic rollout have been verified via formal corporate product announcements from Novartis India and statutory guidelines governing advanced radiopharmaceuticals published by the Central Drugs Standard Control Organisation (CDSCO).
Quote Section
"The introduction of Pluvicto marks a meaningful step forward—bringing globally approved innovation closer to patients who need more targeted treatment options," said Judith Love, Region Head Asia Pacific Middle East Africa at Novartis. "What makes this launch especially impactful is not just the science but the opportunity to expand access through India's growing nuclear medicine infrastructure."
Amitabh Dube, Country President and Managing Director of Novartis India, added: "In India, a large proportion of prostate cancer patients continue to be diagnosed only after the disease has progressed to a metastatic stage, limiting treatment options and impacting quality of life. Beyond the therapy itself, our focus is on building long-term partnerships with hospitals and healthcare stakeholders to help strengthen access pathways."
Why It Matters
The rollout of Pluvicto provides an alternative for advanced prostate cancer patients who have progressed through primary androgen receptor pathway inhibitors (ARPI) and taxane-based chemotherapy regimens. By targeting cancer at the cellular level, the therapy minimizes systemic toxicity compared to traditional cytotoxic chemotherapies, allowing patients to pursue clinical progression-free survival while minimizing heavy physical side effects like severe hair loss or immune collapse.
Key Facts at a Glance
Therapy Name: Pluvicto (lutetium Lu 177 vipivotide tetraxetan).
Primary Indication: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Mechanism of Action: Radioligand therapy combining a targeting ligand with radioactive lutetium-177.
Administration Protocol: Intravenous infusion administered in specialized nuclear medicine facilities.
Distribution Strategy: Partnership-based availability across select specialized hospital networks in India.
FAQ Section
What type of cancer is Pluvicto approved to treat in India?
Pluvicto is specifically approved for adult patients diagnosed with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This means the cancer has spread to other parts of the body and no longer responds to standard medical treatments designed to lower testosterone.
How do doctors determine if a patient is eligible for this therapy?
Before receiving the treatment, patients must undergo a specialized diagnostic imaging scan, such as a PSMA PET scan. This scan verifies whether the cancer cells express the specific PSMA protein target required for the Pluvicto molecule to successfully bind and deliver radiation.
What are the most common side effects associated with Pluvicto?
Based on global clinical trial data, the most frequently reported adverse effects include dry mouth (xerostomia), fatigue, nausea, constipation, decreased appetite, and reduced blood cell counts (anemia or myelosuppression).
Why does this treatment need to be restricted to select hospitals?
Because Pluvicto is a radiopharmaceutical that carries a therapeutic radioactive isotope, it requires highly regulated logistics, custom radiation shielding, and certified nuclear medicine professionals to handle, store, administer, and manage the therapy safely.
Sources:
Official Product Launch and Executive Statements from Novartis India.
Clinical Data Registry and Regulatory Filings via the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India.
